Home
>
UW alum helps develop a B cell–based immunotherapy for cancers linked to HPV infection
UW alum helps develop a B cell–based immunotherapy for cancers linked to HPV infection
Thomas L. Cherpes DVM’89 and Rodolfo D. Vicetti Miguel, investigators with the Ohio State University (OSU) Department of Otolaryngology and Comprehensive Cancer Center (CCC) developed a B cell–based immunotherapy that activates the immune system to fight cancers linked to high-risk human papillomavirus (HPV) infection. Through the Drug Development Institute at the OSU CCC, the university has partnered with Activate Biosciences as an industrial development partner to move this novel immunotherapy into clinical testing. First-in-human clinical testing is expected to start at the OSU CCC in 18 to 24 months. HPV is a large group of viruses spread through skin-to-skin and oral contact. High-risk strains of the virus have long been linked to increased risk of cervical cancer and are also strongly linked to cancers of the head and neck.
